Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab
Background and purposeBiologic therapies are anticipated to dominate the treatment landscape for neuromyelitis optica spectrum disorders (NMOSD) in the future. Despite this, many patients in China continue to use off-label medications due to economic and other constraints. A multicenter NMOSD cohort...
Saved in:
| Main Authors: | Jing Zhou, Xiaolin Yang, Xinyi Wang, Bin Li, Yun Xu, Haoran Zhang, Yinxin Zhu, Xiaoming Wang, Jinzhou Feng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1559118/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders
by: Ana Beatriz Ayroza Galvão Ribeiro GOMES, et al.
Published: (2021-03-01) -
Anti-B-cell therapy in patients with neuromyelitis optica spectrum disorders
by: S. V. Kotov, et al.
Published: (2021-08-01) -
Neuromyelitis Optica: A Case Report
by: Wei-Chia Chia, et al.
Published: (2010-12-01) -
Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes
by: Yao Wang, et al.
Published: (2025-05-01) -
Neuromyelitis Optica Lesion Mimicking Brainstem Glioma
by: J Gordon Millichap
Published: (2007-12-01)